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Purpose: The purpose of this study was to investigate whether
preemptive dosing with lumiracoxib is more effective than post-
operative dosing in reducing post-operative pain associated with
ambulatory arthroscopic knee surgery.
Methods: A multicenter, randomized, double-blind, placebo con-
trolled, parallel group study comparing lumiracoxib 400 mg given
preemptively versus post-operatively in adult patients undergo-
ing minor ambulatory arthroscopic knee surgery (e.g. removal,
trimming, shaving or repair of meniscal or articular cartilage
including lavage). Eligible patients were randomized to either
lumiracoxib 400 mg given preemptively (1 hour before start of
surgery); lumiracoxib 400 mg given post-operatively (15 minutes
after the completion of surgery); and placebo in a 2:2:1 ratio.
The primary endpoint was the pain intensity (PI) after movement
in the target knee 2 hours after surgery based on a 0-100 mm
Visual Analog Scale (VAS) using Wilcoxon rank sum test. The
secondary endpoints included time to rescue medication intake,
PI at 1, 2, 3, 4 and 24 hours while at rest, and PI at 1, 3, 4 and
24 hours after movement, and both measured on a 0-100 mm
VAS using Logrank test.
Results: In total, 110 patients were randomized (lumiracoxib pre-
emptive n=45, lumiracoxib post-operative n=44, placebo n=21),
and all patients completed the study. The difference in me-
dian PI after movement at 2 hours in the lumiracoxib preemp-
tive group (PI=2.75) compared to the lumiracoxib post-operative
group (PI=3.50) in the intent-to-treat (ITT) population was 0.0
(95%CI: -2,1), p=0.602; while lumiracoxib preemptive and post-
operative groups compared to the placebo (PI=9) were -4.0
(95%CI: -9,-1), p=0.007 and -3.5 (95%CI: -8.5,0), p=0.052 re-
spectively.
The time to rescue medication intake was signiﬁcantly longer
for lumiracoxib preemptive (p=0.003) and post-operative groups
(p=0.001) compared to placebo using Logrank test (Figure 1).
The difference in median PI (at rest) post-surgery was not statis-
tically signiﬁcant between the lumiracoxib preemptive group and
Figure 1. Time-to-ﬁrst rescue medication (ITT population).
the post-operative group at any timepoints (1, 2, 3, 4 and 24
hours).
The difference in median PI (at rest) post-surgery for lumiracoxib
preemptive and post-operative groups compared to the placebo
was statistically signiﬁcant at 2, 3, 4 and 24 hours.
The difference in median PI (after movement) post-surgery was
not statistically signiﬁcant between the lumiracoxib preemptive
group and the post-operative group at any timepoints (1, 3, 4
and 24 hours).
The difference in median PI (after movement) post-surgery for
lumiracoxib preemptive and post-operative groups compared to
placebo was statistically signiﬁcant at 1, 3, 4 and 24 hours.
The proportion of patients with adverse events (AEs) were similar
for lumiracoxib preemptive (4.4%), post-operative (4.5%) and
placebo (4.8%), with no serious AEs reported.
Conclusions: Preemptive or postoperative dosing of lumiracoxib
400 mg od had similar efﬁcacy in reducing post-operative pain
following ambulatory arthroscopic knee surgery
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Purpose: An autologous preparation rich in growth factors
(PRGF) secretes a complex mixture of biological mediators es-
sential for natural repair, including TGF-ß1, PDGF, VEGF, HGF
and IGF-I. Due to the localized nature of OA, the possibility of
intra-articular administration of PRGF, along with its biocompati-
bility and non-immunogenicity, may make this unique molecular
mixture an attractive treatment for OA.
Purpose: (1) To explore the potential clinical beneﬁts of PRGF
injections for the treatment of OA in a retrospective observational
study. (2) To characterize the PRGF treatment in OA patients.
Methods: A total of 112 patients with symptomatic knee OA were
treated with a series of three weekly intra-articular injections
of PRGF and studied retrospectively. Anterio-posterior weight-
bearing radiographs were scored for Ahlbäck severity grade.
In bilateral patients, the Ahlbäck grade used for analyses was
the higher of the two knees. The primary efﬁcacy criteria were
mean change from baseline through two and six months in the
WOMAC index pain and physical function subscale scores and
global WOMAC assessment at month two and six. A repeated
measures ANCOVA model was used to compare clinical parame-
ters at baseline and at follow-up. Age, gender, Ahlbäck grade and
BMI were included in the models. Success rates were calculated
as a reduction in the WOMAC pain score of at least 40% from
baseline and a 35% reduction in the physical function and global
WOMAC scores. For preparation of the PRGF treatment, unco-
agulated peripheral blood was collected from the patient; after
one single-step centrifugation, the plasma fraction located just
above the buffy coat was aspirated and dispensed into an empty
tube under vertical air ﬂow conditions. Platelet activation was in-
duced by CaCl2 addition a few minutes prior to PRGF inﬁltration.
Enzyme-linked immunosorbent assays were used for determin-
ing levels of PDGF-AB, VEGF, HGF, IGF-I and TGF-β1 in PRGF.
Results: The mean age of the participants was 67 years (range:
42-91). Of the participants, 63% were female and the average
BMI was 28 kg/m2 (range: 21-40). Of the 112 knee radiographs
included in the study, twenty-three (20%) were graded Ahlbäck I,
50 (45%) were graded Ahlbäck II, 29 (26%) were graded Ahlbäck
III and 10 (9%) were graded Ahlbäck IV. The differences between
pain subscale scores at baseline and two or six months were
